Use of risk-based cervical screening programs in resource-limited settings.

[1]  J. Kaldor,et al.  Point-of-care HPV DNA testing of self-collected specimens and same-day thermal ablation for the early detection and treatment of cervical pre-cancer in women in Papua New Guinea: a prospective, single-arm intervention trial (HPV-STAT). , 2022, The Lancet. Global health.

[2]  Kanan T. Desai,et al.  Redesign of a rapid, low‐cost HPV typing assay to support risk‐based cervical screening and management , 2022, International journal of cancer.

[3]  A. Wisniak,et al.  Addition of digital VIA/VILI to conventional naked-eye examination for triage of HPV-positive women: A study conducted in a low-resource setting , 2022, PloS one.

[4]  J. Tille,et al.  ABCD criteria to improve visual inspection with acetic acid (VIA) triage in HPV-positive women: a prospective study of diagnostic accuracy , 2022, BMJ Open.

[5]  A. Wisniak,et al.  Training, Supervision, and Competence Assessment of Cameroonian Health Care Providers Using HPV Self-Sampling, Triage by Visual Inspection, and Treatment by Thermal Ablation in a Single Visit , 2022, Frontiers in Public Health.

[6]  Kanan T. Desai,et al.  Contribution of Etiologic Cofactors to CIN3+ Risk Among Women With Human Papillomavirus–Positive Screening Test Results , 2022, Journal of lower genital tract disease.

[7]  Paul C. Pearlman,et al.  The development of “automated visual evaluation” for cervical cancer screening: The promise and challenges in adapting deep‐learning for clinical testing , 2021, International journal of cancer.

[8]  S. Sangrajrang,et al.  The IARC Perspective on Cervical Cancer Screening. , 2021, The New England journal of medicine.

[9]  J. Berkhof,et al.  Clinical performance of high-risk HPV testing on self-samples versus clinician samples in routine primary HPV screening in the Netherlands: An observational study. , 2021, The Lancet regional health. Europe.

[10]  L. Bruni,et al.  Worldwide use of HPV self-sampling for cervical cancer screening. , 2021, Preventive medicine.

[11]  Lesego Gabaitiri,et al.  Support for lowering cervical cancer screening age to 25 for women living with HIV: retrospective cross-sectional programmatic data from Botswana , 2021, BMC Women's Health.

[12]  Jane J. Kim,et al.  Cost-effectiveness Analysis of the 2019 ASCCP Risk-Based Management Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors. , 2021, American journal of obstetrics and gynecology.

[13]  N. Wentzensen,et al.  Treatment approaches for women with positive cervical screening results in low-and middle-income countries. , 2021, Preventive medicine.

[14]  Kanan T. Desai,et al.  A proposed new generation of evidence-based microsimulation models to inform global control of cervical cancer. , 2021, Preventive medicine.

[15]  L. R. Long,et al.  Design and feasibility of a novel program of cervical screening in Nigeria: self-sampled HPV testing paired with visual triage , 2020, Infectious agents and cancer.

[16]  P. Castle,et al.  Outcomes for Step-Wise Implementation of a Human Papillomavirus Testing–Based Cervical Screen-and-Treat Program in El Salvador , 2020, JCO global oncology.

[17]  M. Schiffman,et al.  A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs , 2020, EClinicalMedicine.

[18]  M. Schiffman,et al.  Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines , 2020, Journal of lower genital tract disease.

[19]  M. Schiffman,et al.  2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors , 2020, Journal of lower genital tract disease.

[20]  M. Schiffman,et al.  A Study of Partial Human Papillomavirus Genotyping in Support of the 2019 ASCCP Risk-Based Management Consensus Guidelines , 2020, Journal of lower genital tract disease.

[21]  Mayoore S. Jaiswal,et al.  An Observational Study of Deep Learning and Automated Evaluation of Cervical Images for Cancer Screening. , 2019, Journal of the National Cancer Institute.

[22]  S. Temin,et al.  Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses , 2018, British Medical Journal.

[23]  C. Blat,et al.  Evaluating a community-based cervical cancer screening strategy in Western Kenya: a descriptive study , 2018, BMC Women's Health.

[24]  J. Singer,et al.  Community-based HPV self-collection versus visual inspection with acetic acid in Uganda: a cost-effectiveness analysis of the ASPIRE trial , 2018, BMJ Open.

[25]  M. Arbyn,et al.  Accuracy of combinations of visual inspection using acetic acid or lugol iodine to detect cervical precancer: a meta‐analysis , 2018, BJOG : an international journal of obstetrics and gynaecology.

[26]  M. Schiffman,et al.  Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test. , 2014, Journal of the National Cancer Institute.

[27]  T. Wright,et al.  Clinical Evaluation of the Cartridge-Based GeneXpert Human Papillomavirus Assay in Women Referred for Colposcopy , 2014, Journal of Clinical Microbiology.

[28]  R. Dikshit,et al.  Effect of VIA screening by primary health workers: randomized controlled study in Mumbai, India. , 2014, Journal of the National Cancer Institute.

[29]  P. Hillemanns,et al.  Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. , 2014, The Lancet. Oncology.

[30]  Y. Qiao,et al.  Lower cost strategies for triage of human papillomavirus DNA-positive women , 2013, International journal of cancer.

[31]  Diane Solomon,et al.  2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. , 2013, Obstetrics and gynecology.

[32]  Peng Guan,et al.  Human papillomavirus types in 115,789 HPV‐positive women: A meta‐analysis from cervical infection to cancer , 2012, International journal of cancer.

[33]  David R. Scott,et al.  Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  R. Sankaranarayanan,et al.  HPV screening for cervical cancer in rural India. , 2009, The New England journal of medicine.

[35]  Feng Chen,et al.  A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. , 2008, The Lancet. Oncology.

[36]  Jose Jeronimo,et al.  Human papillomavirus and cervical cancer , 2007, The Lancet.

[37]  S. Franceschi,et al.  Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. , 2006, Vaccine.

[38]  Eric Lucas,et al.  Accuracy of visual screening for cervical neoplasia: Results from an IARC multicentre study in India and Africa , 2004, International journal of cancer.

[39]  M. Schiffman,et al.  Epidemiologic studies of a necessary causal risk factor: human papillomavirus infection and cervical neoplasia. , 2003, Journal of the National Cancer Institute.

[40]  Z. Chirenje,et al.  A randomised clinical trial of loop electrosurgical excision procedure (LEEP) versus cryotherapy in the treatment of cervical intraepithelial neoplasia. , 2001, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.